The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award

On June 28, Chuansha Park of Shanghai Medicilon Inc. (Medicilon) welcomed familiar customers - Dr. Yan Feng, Founder and CEO of Leading Tac Pharma, Dr. Juan XU, VP of Bioanalysis and Proteomics, and a group of colleagues. This time, Dr. Feng Yan and his party visited Medicilon in person, just to award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition. Professor Shuangqing Peng, Chief Scientific Officer of Medicilon, and Dr. Pin Jiang, Director of the Department of Pharmacokinetics and Bioanalysis, warmly received and had an fruitful discussion.

CEO of Leading Tac Pharma came to present the DMPK award.webp

During the symposium, the two parties actively interacted, offered suggestions, shared the latest scientific and technological achievements and R&D experience around their respective advantages and needs, discussed in depth the status quo, development trends of the biomedical industry, and project R&D strategies, and clarified the next step of the project's planning and deployment, laying a solid foundation for further collaboration between the two parties.

DMPK award from Leading Tac Pharma.webp

At the awarding ceremony, Dr. Feng affirmed Medicilon's consistently rigorous, efficient and high-quality preclinical R&D services, and praised Medicilon's dedicated work attitude in DMPK, bioanalysis, and project management. He then expressed his sincere gratitude and awarded honorary trophies to Medicilon DMPK team. The DMPK team has a group of senior professionals with solid knowledge and rich experimental experience, leading the work of experimental design, experimental implementation, biological analysis and data analysis. At present, the pharmacokinetic laboratory has passed the GLP certification of NMPA. The experimental research follows the guidelines of ICH, NMPA and FDA, and can design and carry out in vivo and in vitro pharmacokinetic tests according to client needs, providing clients with a complete set of pharmacokinetic evaluation and optimization services.

About Leading Tac Pharma
Founded in 2019, Leading Tac Pharma is a biopharmaceutical company dedicated to the research and development of First-in-class/Best-in-class small molecule innovative drugs. With Targeted Protein Degradation (TPD) drug development technology as the core, it focuses on autoimmunity and tumors, two therapeutic areas with important market opportunities and synergistic effects, to provide patients with breakthrough treatment options. Leading Tac Pharma is located in Zhangjiang Science City, Shanghai, China. The existing laboratory and office area is nearly 1,000 square meters, and there are 20 employees. It has completed financing of nearly RMB 100 million since its establishment 3 years ago.

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客